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ABSTRACT
A novel diversity-oriented post-Ugi/gold(I)-catalyzed heteroannulation process for the synthesis of imidazo[1,4]diazepin-7-ones is elaborated. The
scope and limitations of the protocol are discussed.
Homogeneous gold-catalyzed carbocyclization and het-
eroannulation strategies have become a particularly active
research area due to the exceptional ability of gold com-
plexes to activate alkynes, alkenes, and allenes toward
nucleophilic attack.1 The rediscovering of this coinage
metal in homogeneous catalysis allowed a significant
expansion of the current synthetic scenario for selective
manipulations of unactivated unsaturated hydrocarbons.
The gold-catalyzed intramolecular cyclizations of aro-
matic and heteroaromatic compounds with alkynes offer
new pathways for the efficient construction of bioactive
compounds.2,3
Figure 1. Drugs possessing the imidazo[1,4]diazepin-7-one
skeleton.
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The imidazodiazepinone core is ubiquitous in various
natural and synthetic pharmaceuticals4 as well as vital
intermediates in the synthesis of pentostanin5 and
coformycin,6 both naturally occurring anticancer and
antiviral nucleosides. The commercially available drug
bretazenil7 is used as a partial agonist for GABAA receptors
due to its high affinity to the benzodiazepinone binding site.
On the other hand, flumazenil8 is a high-affinityGABAA-BZ
site antagonist that has been used clinically to treat
benzodiazepine intoxication9 (Figure 1). Most synthetic
approaches toward imidazo[1,4]diazepinones involvemulti-
ple-step sequences and harsh conditions and are limited in
scope of the substitution pattern of the scaffold.10 Conse-
quently, it would be highly desirable to develop a more
versatile and milder route for these compounds. Through
the years, multicomponent reactions (MCRs)11 have
received increasing attention due to their simplicity, effi-
ciency, atom economy, shortend reaction times, and the
possibilty for diversity-oriented synthesis. The combination
of MCRs with transition metal-catalysis gives access to
complex molecules in few steps as compared to traditional
multistep processes. We have recently developed a sequen-
tial post-Ugi gold(I)-catalyzed intramolecular hydroar-
ylation approach for the synthesis of indolazocines,12
spiroindolines,13 pyrroloazepinones, and pyrrolopyridi-
nones.14 Inspired by these findings and as a result of our
interest in exploring the synthetic utility of both transi-
tion metal catalysis15 and multicomponent reactions,16 we
have developed an expedient post-Ugi intramolecular
Table 1. Optimization of the Reaction Conditionsa





1 AuCl (10) CDCl3 24 100 (80)
2 AuCl3(10) CDCl3 24 100 (72)
3 Au(PPh3)Cl (10) CDCl3 24 20
4 Au(PPh3)OTf (10) CDCl3 10 100 (96)
5 Au(PPh3)SbF6(10) CDCl3 24 60
6c Au(PPh3)BF4(10) CDCl3 24 65
7 Au(PPh3)BF4(10) CDCl3 4 100 (98)
8 Au(PPh3)NTf2(10) CDCl3 24 100 (96)
9 Au(X-PhOS)NTf2(10) CDCl3 12 100(92)
10 [MeCN(JohnPhos)Au] SbF6 (10) CDCl3 24 100 (90)
11 AgBF4 (10) CDCl3 24 100(84)
12 Cu(I)OTf (10) CDCl3 24 0
13 Sc(III)(OTf)3 (10) CDCl3 24 5
14 Bi(III)(OTf)3 (10) CDCl3 24 25
15 Au(PPh3)BF4(10) ACN-d3 6 100 (86)
16 Au(PPh3)BF4(10) THF-d8 24 90
17 Au(PPh3)BF4(5) CDCl3 24 45
18 CDCl3 24 traces
aAll reactions were run on a 0.13 mmol scale of 5a in a screw-capped
vial at 70 C. bConversion based on 1H NMR analysis; yields given in
parentheses are isolated yields. cReaction at 50 C. Tf = Trifluoro-
methanesulfonyl, X-Phos =2-dicyclohexylphosphino-204060-triisopro-
pylbiphenyl, JohnPhos = (2-biphenyl)di-tert-butylphosphine, PMB =
p-methoxybenzyl.
(4) (a) Showalter, H. D. H.; Putt, S. R.; Borondy, P. E.; Shillis, J. L.
J. Med. Chem. 1983, 26, 1478. (b) Saville-Stones, E. A.; Turner, R. M.;
Lindell, S. D.; Jennings, N. S.; Head, J. C.; Carver, D. S.Tetrahedron 1994,
50, 6695. (c) Kasibhatla, S. R.; Bookser, B. C.; Xiao, W.; Erion, M. D.
J. Med. Chem. 2001, 44, 613. (d) Bookser, B. C.; Kasibhatla, S. R.; Erion,
M. D. J. Med. Chem. 2000, 43, 1519. (e) Kasibhatla, S. R.; Bookser, B. C.;
Probst, G.; Appleman, J. R.; Erion, M. D. J. Med. Chem. 2000, 43, 1508.
(f) Kasibhatla, S. R.; Bookser, B. C.; Appleman, J. R.; Erion, M. D.
J.Med. Chem. 2000, 43, 1495. (g) Erion,M.D.;Kasibhatla, S.R.; Bookser,
B. C.; van Poejie, P. D.; Reddy, M. R.; Gruber, H. E.; Appleman,
J. R. J. Am. Chem. Soc. 1999, 121, 308. (h) Kiec-Kononowicza,
K.; Karolak-Wojciechowskab, J.; M€ullerc, C. E.; Schumacher, B.;
Pekalaa, E.; Szyma~nskaa, E. Eur. J. Med. Chem. 2001, 36, 407.
(I)Chen,B-C;Chao,S.T; Sundeen, J.E.;Tellew, J.;Ahmad,S.Tetrahedron
Lett. 2002, 43, 1595.
(5) Baker, D. C.; Putt, S. R. J. Am. Chem. Soc. 1979, 101, 6127.
Showalter, H. D. H.; Putt, S. R. Tetrahedron Lett. 1981, 22, 3155. Chan,
E.; Putt, S. R.; Showalter, H.D.H.; Baker, D. C. J. Org. Chem. 1982, 47,
3457.
(6) Hawkins, L. D.; Hanvey, J. C.; Boyd, F. L., Jr.; Baker, D. C.
Nucleosides Nucleotides 1983, 2, 479.
(7) Tashma, Z.; Raveh, L.; Liani,H.;Alkalay,D.;Givoni, S.;Kapon,
J.; Cohen, G.; Alcalay, M.; Grauer, E. J. Appl. Toxicol. 2001, 21, S115.
(8) (a) Lancel,M.; Steiger, A.Angew. Chem., Int. Ed. 1999, 111, 2852.
(b) Moran, M. D.; Wilson, A. A.; Elmore, C. S.; Parkes, J.; Ng, A.;
Sadovski,O.;Graff, A.; Daskalakis, Z. J.;Houle, S.; Chapdelaine,M. J.;
Vasdev, N. Bioorg. Med. Chem. 2012, 20, 4482.
(9) Lheureux, P.; Askenasi, R. Hum. Toxicol. 1988, 7, 165.
(10) (a) Achermann, G.; Ballard, T. M.; Blasco, F.; Broutin, P.-E.;
Buttelmann, B.; Fischer, H.; Graf, M.; Hernandez, M.-C.; Hilty, P.;
Knoflach, F.; Koblet, A.; Knust, H.; Kurt, A.;Martin, J. R.;Masciadri,
R.; Porter, R. H. P.; Stadler, H.; Thomas, A.W.; Trube, G.;Wichmann,
J. Bioorg. Med. Chem. Lett. 2009, 19, 5746. (b) Watjen, F.; Baker, R.;
Engelstoff, M.; Herbert, R.; MacLeod, A.; Knight, A.; Merchant, K.;
Moseley, J.; Saunders, J.; Swain, C. J.; Wong, E.; Springer, J. P. J. Med.
Chem. 1989, 32, 2282. (c) Zhang, P.; Zhang, W.; Liu, R.; Harris, B.;
Skolnick, P.; Cook, J. M. J. Med. Chem. 1995, 38, 1679. (d) Li, X.; Cao,
H.; Zhang, C.; Furtmueller, R.; Fuchs, K.; Huck, S.; Sieghart, W.;
Deschamps, J.; Cook, J.M. J.Med. Chem. 2003, 46, 5567. (e) Li, X.; Yu,
J.; Atack, J. R.; Cook, J. M.Med. Chem. Res. 2004, 13, 259. (f) Marcos,
A.; Pedregal, C.; Avendailo, C. Tetrahedron 1991, 41, 1459. (g) Rogers-
Evans, M.; Spurr, P.; Hennig, M. Tetrahedron Lett. 2003, 44, 2425.
(h) Donohue, S. R.; Dannals, R. F. Tetrahedron Lett. 2009, 50, 7271.
(11) For isonitrile-basedmulticomponent reactions, see (a)D€omling,
A.; Ugi, I.Angew. Chem., Int. Ed. 2000, 39, 3168. (b) D€omling, A.Chem.
Rev. 2006, 106, 17. For multicomponent reactions with indoles, see:
(c) Shriri, M.Chem. Rev. 2012, 112, 3508. For asymmetric multicompo-
nent reactions, see: (d) Ramon, D. J.; Yus, M. Angew. Chem., Int. Ed.
2005, 44, 1602. For multicomponent reactions in general, see: (e)
Ganem, B. Acc. Chem. Res. 2009, 42, 463. (f) ElKaı¨m, L.; Grimaud,
L. Mol. Diversity 2010, 14, 855. (g) Ruijter, E.; Scheffelaar, R.; Orru,
R. V. A. Angew.Chem., Int. Ed. 2011, 50, 6234. (h) D€omling, A.; Wang,
W.; Wang, K. Chem. Rev. 2012, 112, 3083.
(12) Modha, S. G.; Vachhani, D. D.; Jacobs, J.; Van Meervelt, L.;
Van der Eycken, E. V. Chem. Commun. 2012, 48, 6550.
(13) Modha, S. G.; Kumar, A.; Vachhani, D. D.; Jacobs, J.; Sharma,
S. K.; Parmar, V. S.; Van Meervelt, L.; Van der Eycken, E. V. Angew.
Chem., Int. Ed. 2012, 51, 9572.
(14) Modha, S. G.; Kumar, A.; Vachhani, D. D.; Jacobs, J.; Sharma,
S. K.; Parmar, V. S.; Van Meervelt, L.; Van der Eycken, E. V. Chem.
Commun. 2012, 48, 10916.
(15) (a)Modha, S. G.; Trivedi, J. C.;Mehta, V. P.; Ermolat’ev, D. S.;
Van der Eycken, E. V. J. Org. Chem. 2011, 76, 846. (b)Mehta, V. P.; Van
der Eycken, E. V.Chem. Soc. Rev. 2011, 40, 4925. (c) Kappe, C. O.; Van
der Eycken, E. V.Chem. Soc. Rev. 2010, 39, 1280. (d) Donets, P. A.; Van
Hecke, K.; VanMeervelt, L.; Van der Eycken, E. V.Org. Lett. 2009, 11,
3618. (e) Donets, P. A.; Van der Eycken, E. V. Synthesis 2011, 2147.
(f) Modha, S. G.; Mehta, V. P.; Ermolat’ev, D. S; Balzarini, J.; Van
Hecke,K.; VanMeervelt, L.; Van der Eycken, E. V.Mol. Diversity 2010,
14, 767.
(16) (a)Mehta, V. P.; Modha, S. G.; Ruijter, E.; VanHecke, K.; Van
Meervelt, L.; Pannecouque, C.; Balzarini, J.; Orru, R. V. A.; Van der
Eycken, E. V. J. Org. Chem. 2011, 76, 2828. (b) Peshkov, V. A.;
Pereshivko,O. P.; Van der Eycken, E. V.Chem. Soc. Rev. 2012, 41, 3790.
1876 Org. Lett., Vol. 15, No. 8, 2013
heteroannulation approach for the synthesis of imidazo-
diazepinones.
Ugi 4-CR11 of imidazole-4-carbaldehyde (1a), p-meth-
oxybenzylamine (2a), 2-butynoic acid (3a), and tert-butyl
isonitrile (4a) inmethanol at rt furnishes the corresponding
Ugi adduct 5a in 84% yield. This compound was used to
check the feasibility of the intramolecular heteroannula-
tion. The application of 10 mol % of AuCl or AuCl3 as
catalyst produced imidazodiazepinone 6a in 100% con-
versionwith a yield of 80 and 72%, respectively, while only
20% conversion was observed with Au(PPh3)Cl (Table 1,
entries 13). The use of Au(PPh3)OTf (10 mol %) gave
100% conversion in 10 h with a yield of 96%, while only
60% conversion was observed with Au(PPh3)SbF6 after
24 h (Table 1, entries 4 and 5). Au(PPh3)BF4 (10mol%) at
50 C furnished 65% conversion, while heating at 70 C
resulted in 100% conversion in just 4 h with a yield of
98% (Table 1, entry 6 and 7). Also Au(PPh3)NTf2, Au(X-
Phos)NTf2, and with Au(PPh3)Cl (Table 1, entries 13).
The use of Au(PPh3)OTf (10 mol %) gave 100% conver-
sion in 10hwith a yield of 96%,while only 60%conversion
was observed with Au(PPh3)SbF6 after 24 h (Table 1,
entries 4 and 5). Au(PPh3)BF4 (10 mol %) at 50 C
furnished 65% conversion, while heating at 70 C resulted
in 100%conversion in just 4 hwith a yield of 98% (Table 1,
entry 6 and 7). Also Au(PPh3)NTf2, Au(X-Phos)NTf2,
and [MeCN(JohnPhos)Au]SbF6 gave 100% conversion
with excellent yields but with longer reaction times
(Table 1, entries 810). Although the reaction with the
comparitivily cheaper AgBF4 was found to be feasible,
a longer reaction time was required (Table 1, entry 11).
No amelioration was observed with CuOTf, Sc(OTf)3 or
Bi(OTf)3, (Table 1, entries 1214). In the case of cationic
gold-catalysis, changing the solvent into ACN-d3 resulted
in a decreased yield, while in THF-d8 a lower conversion
was obtained (Table 1, entries 15 and 16). Diminishing
the catalyst loading to 5 mol % resulted in a decreased
conversion (Table 1, entry 17). No conversion was ob-
tained without catalyst (Table 1, entry 18).
To evaluate the scope and limitations of our optimized
protocol (Table 1, entry 7), different Ugi adducts (5ar)
were synthesized from imidazole-4-carbaldehyde (1a) and
subjected to the intramolecular heteroannulation reaction
(Table 2). Various substituents related to the alkyne, the
isonitrile, the imidazole, and the amine are tolerated giving
good to excellent yields. A bulky substituent like a phenyl
group on the alkyne consistently reduced the reaction rate,
increasing the temperature to 80 C and the time to 72 h
with 20 mol % of catalyst loading, leading to an isolated
yield of 82% (Table 2, 6e). When the Ugi adduct contain-
ing a terminal alkyne was subjected to the optimized
conditions, the exclusive formation of the endo product
was observed in 75% isolated yield (Table 2, 6q).
On the basis of previous investigations of related
cyclizations,2,1013 a plausible mechanism for this gold(I)-
catalyzed intramolecular heteroannulation reaction is
depicted in Scheme 1. The coordination of the metal with
the alkyne in the Ugi-adduct 5a generates intermediate A.
Nucleophilic attack of the imidazole on the activated
Table 2. Scope of the Intramolecular Heteroannulation
Reactiona
yield (%)






a H H PMB Me t-Bu 84 98 (84)b
b H H PMB Me Cy 82 94 (65)b
c H H PMB Me n-Bu 75 90
d H H PMB Et t-Bu 73 92
e H H PMB Ph t-Bu 62 82c
f H Me PMB Me Cy 54 79
g H H piperonyl Me t-Bu 57 89
h H H piperonyl Et t-Bu 63 93 (76)b
i H Me piperonyl Me t-Bu 47 96 (68)b
j H H piperonyl Me Cy 71 86 (74)b
k H H 3,4-DMB Me t-Bu 70 90 (81)b
l H Me 3,4-DMB Me Cy 50 96
m H H 3,4-DMB Me Cy 97 97
n H H 3,4-DMB Et Cy 63 82
o H Me PMB Me t-Bu 63 95
p H H Bn Me Cy 34 88
q H H 3,4-DMB H t-Bu 85 75
r Me H PMB Me t-Bu 55 77
aAll reactionswere runon a 0.25mmol scale of 5awithAu(PPh3)BF4
(10 mol %) and CHCl3 (2 mL) in a screw capped vial at 70 C for 4 h.
bThe reactionwas carried usingAgBF4 (10mol%) at 70 C for 2430 h.
cAu(PPh3)BF4 (20 mol %) was used at 80 C for 72 h. 3,4-DMB= 3,4-
dimethoxybenzyl.
Scheme 1. Plausible Mechanism for the Gold-Catalyzed
Heteroannulation
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alkyne occurs in an endo-dig fashion generating a 7-mem-
bered ring intermediate B, which upon deprotonation and
protodeauration forms imidazodiazepinone 6a.
In summary, we have elaborated a novel diversity-
oriented approach for the synthesis of interesting imidazo-
[1,4]diazepin-7-ones starting from readily available build-
ing blocks. The first step, theUgi-4CR, generates diversity,
while the second step, an efficient gold(I)-catalyzed hetero-
annulation, results in the formation of the imidazo[1,4]-
diazepin-7-one scaffold.
Acknowledgment. We thank the FWO [Fund for Scien-
tific Research - Flanders (Belgium)] and theResearch Fund
of the University of Leuven (KU Leuven) for financial
support. A.K. is thankful to EMA2experts (ErasmusMun-
dusAction 2, Lot 11Asia: Experts) for providing a doctoral
exchange scholarship, and Z.L. is thankful to the CSC
(China Scholarship Council) for providing a doctoral
scholarship.
Supporting Information Available. General experimen-
tal details and spectroscopic data for all new compounds.
This material is available free of charge via the Internet at
http://pubs.acs.org.
The authors declare no competing financial interest.
